Chart Review of Repatha® in Subjects With Hyperlipidaemia
NCT ID: NCT02770131
Last Updated: 2024-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1986 participants
OBSERVATIONAL
2016-05-04
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
National Survey on Dyslipidemic Patients
NCT00701402
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
NCT00327418
Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
NCT00309751
Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH
NCT04034485
Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia
NCT00141141
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
To describe the clinical characteristics of subjects at initiation of Repatha® (up to 2000 subjects).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Feldkirch, , Austria
Research Site
Graz, , Austria
Research Site
Innsbruck, , Austria
Research Site
Klagenfurt, , Austria
Research Site
Linz, , Austria
Research Site
Salzburg, , Austria
Research Site
Vienna, , Austria
Research Site
Vienna, , Austria
Research Site
Vienna, , Austria
Research Site
Vienna, , Austria
Research Site
Villach, , Austria
Research Site
Aalst, , Belgium
Research Site
Genk, , Belgium
Research Site
Ghent, , Belgium
Research Site
La Louvière, , Belgium
Research Site
Leuven, , Belgium
Research Site
Kostenets, , Bulgaria
Research Site
Pleven, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Stara Zagora, , Bulgaria
Research Site
Varna, , Bulgaria
Research Site
Varna, , Bulgaria
Research Site
Brno, , Czechia
Research Site
České Budějovice, , Czechia
Research Site
Hradec Králové, , Czechia
Research Site
Liberec, , Czechia
Research Site
Olomouc, , Czechia
Research Site
Pilsen, , Czechia
Research Site
Prague, , Czechia
Research Site
Prague, , Czechia
Research Site
Ústí nad Labem, , Czechia
Research Site
Zlín, , Czechia
Research Site
Aachen, , Germany
Research Site
Bad Reichenhall, , Germany
Research Site
Berlin, , Germany
Research Site
Berlin, , Germany
Research Site
Bielefeld, , Germany
Research Site
Bochum, , Germany
Research Site
Borsdorf, , Germany
Research Site
Detmold, , Germany
Research Site
Garbsen, , Germany
Research Site
Germering, , Germany
Research Site
Göttingen, , Germany
Research Site
Halberstadt, , Germany
Research Site
Halle, , Germany
Research Site
Hamburg, , Germany
Research Site
Langenhagen, , Germany
Research Site
Leipzig, , Germany
Research Site
Mainz, , Germany
Research Site
Mannheim, , Germany
Research Site
Markleeberg, , Germany
Research Site
Mönchengladbach, , Germany
Research Site
Mühldorf, , Germany
Research Site
Mülheim, , Germany
Research Site
München, , Germany
Research Site
München, , Germany
Research Site
Neuwied, , Germany
Research Site
Nuremberg, , Germany
Research Site
Oschatz, , Germany
Research Site
Pirna, , Germany
Research Site
Potsdam, , Germany
Research Site
Rostock, , Germany
Research Site
Rotenburg (Wümme), , Germany
Research Site
Viersen-Dülken, , Germany
Research Site
Villingen-Schwenningen, , Germany
Research Site
Zwickau, , Germany
Research Site
Alexandroupoli, , Greece
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Athens, , Greece
Research Site
Heraklion, , Greece
Research Site
Ioannina, , Greece
Research Site
Larissa, , Greece
Research Site
Piraeus, , Greece
Research Site
Thessaloniki, , Greece
Research Site
Thessaloniki, , Greece
Research Site
Thessaloniki, , Greece
Research Site
Acerra, , Italy
Research Site
Arzignano, , Italy
Research Site
Asti, , Italy
Research Site
Bassano Del Grappa (VI), , Italy
Research Site
Bologna, , Italy
Research Site
Brescia, , Italy
Research Site
Brindisi, , Italy
Research Site
Catanzaro, , Italy
Research Site
Cinisello Balsamo (MI), , Italy
Research Site
Cona FE, , Italy
Research Site
Cosenza, , Italy
Research Site
Foggia, , Italy
Research Site
Lido Di Camaiore LU, , Italy
Research Site
Messina, , Italy
Research Site
Mestre (VE), , Italy
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Napoli, , Italy
Research Site
Padua, , Italy
Research Site
Palermo, , Italy
Research Site
Pescara, , Italy
Research Site
Reggio Calabria, , Italy
Research Site
Rivoli, , Italy
Research Site
Roma, , Italy
Research Site
Roma, , Italy
Research Site
Salerno, , Italy
Research Site
Seriate, , Italy
Research Site
Sesto San Giovanni (MI), , Italy
Research Site
Taranto, , Italy
Research Site
Torrette Di Ancona, , Italy
Research Site
Treviglio (BG), , Italy
Research Site
Trieste, , Italy
Research Site
Almada, , Portugal
Research Site
Carnaxide, , Portugal
Research Site
Coimbra, , Portugal
Research Site
Faro, , Portugal
Research Site
Matosinhos Municipality, , Portugal
Research Site
Porto, , Portugal
Research Site
Banská Bystrica, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Brezno, , Slovakia
Research Site
Handlová, , Slovakia
Research Site
Komárno, , Slovakia
Research Site
Košice, , Slovakia
Research Site
Košice, , Slovakia
Research Site
Martin, , Slovakia
Research Site
Martin, , Slovakia
Research Site
Moldava nad Bodvou, , Slovakia
Research Site
Myjava, , Slovakia
Research Site
Námestovo, , Slovakia
Research Site
Nitra, , Slovakia
Research Site
Nitra, , Slovakia
Research Site
Nitra, , Slovakia
Research Site
Nové Mesto nad Váhom, , Slovakia
Research Site
Nové Zámky, , Slovakia
Research Site
Poprad, , Slovakia
Research Site
Prešov, , Slovakia
Research Site
Rožňava, , Slovakia
Research Site
Trnava, , Slovakia
Research Site
Žilina, , Slovakia
Research Site
Cadiz, Andalusia, Spain
Research Site
Huelva, Andalusia, Spain
Research Site
Jaén, Andalusia, Spain
Research Site
Málaga, Andalusia, Spain
Research Site
Seville, Andalusia, Spain
Research Site
Seville, Andalusia, Spain
Research Site
Palma de Mallorca, Balearic Islands, Spain
Research Site
Badalona, Catalonia, Spain
Research Site
Barcelona, Catalonia, Spain
Research Site
Reus, Catalonia, Spain
Research Site
Sabadell, Catalonia, Spain
Research Site
Ferrol, Galicia, Spain
Research Site
Lugo, Galicia, Spain
Research Site
Alcalá de Henares, Madrid, Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Gothenburg, , Sweden
Research Site
Malmo, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Uppsala, , Sweden
Research Site
Basel, , Switzerland
Research Site
Geneva, , Switzerland
Research Site
Lugano, , Switzerland
Research Site
Winterthur, , Switzerland
Research Site
Zurich, , Switzerland
Research Site
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ray KK, Dhalwani N, Sibartie M, Bridges I, Ebenbichler C, Perrone-Filardi P, Villa G, Vogt A, Bruckert E. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. Eur Heart J Qual Care Clin Outcomes. 2022 Jun 6;8(4):447-460. doi: 10.1093/ehjqcco/qcac009.
Blaha V, Margoczy R, Petrov I, Postadzhiyan A, Raslova K, Rosolova H, Bridges I, Dhalwani NN, Zachlederova M, Ray KK. Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study. J Cardiovasc Pharmacol Ther. 2023 Jan-Dec;28:10742484231172847. doi: 10.1177/10742484231172847.
Blanco Echevarria A, Garcia Diaz JD, Caixas A, Plana Gil N, Rico Corral MA, Bridges I, Dhalwani N, Gatell Menchen S, Ray KK. Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study. Clin Investig Arterioscler. 2023 Nov-Dec;35(6):263-271. doi: 10.1016/j.arteri.2023.04.004. Epub 2023 May 24. English, Spanish.
Ebenbichler C, Drexel H, Hanusch U, Toplak H, Dhalwani NN, Bridges I, Hoelzl R, Hemetsberger M, Ray KK. Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study. Wien Klin Wochenschr. 2024 Feb;136(3-4):77-86. doi: 10.1007/s00508-023-02245-w. Epub 2023 Jul 31.
Sudano I, Krahenbuhl S, Mach F, Anstett A, Dhalwani N, Bridges I, Sibartie M, Ray KK. Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study. Ther Adv Cardiovasc Dis. 2024 Jan-Dec;18:17539447231213288. doi: 10.1177/17539447231213288.
Lehrke M, Vogt A, Schettler V, Girndt M, Fraass U, Tabbert-Zitzler A, Bridges I, Dhalwani NN, Ray KK. Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Adv Ther. 2024 Mar;41(3):1184-1200. doi: 10.1007/s12325-023-02757-x. Epub 2024 Jan 30.
Vlachopoulos C, Massia D, Kochiadakis G, Kolovou G, Patsilinakos S, Bridges I, Sibartie M, Dhalwani NN, Liberopoulos E, Ray KK. Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study. Hellenic J Cardiol. 2023 Nov-Dec;74:74-76. doi: 10.1016/j.hjc.2023.09.003. Epub 2023 Sep 18. No abstract available.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20130296
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.